ECSP982571A - SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS - Google Patents
SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMSInfo
- Publication number
- ECSP982571A ECSP982571A ECSP982571A ECSP982571A EC SP982571 A ECSP982571 A EC SP982571A EC SP982571 A ECSP982571 A EC SP982571A EC SP982571 A ECSP982571 A EC SP982571A
- Authority
- EC
- Ecuador
- Prior art keywords
- sertralina
- sertraline
- dosage forms
- salt
- release dosage
- Prior art date
Links
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical class C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 7
- 239000002552 dosage form Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 229960002073 sertraline Drugs 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 150000003895 L-lactate salts Chemical class 0.000 abstract 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 abstract 1
- 159000000021 acetate salts Chemical class 0.000 abstract 1
- 229940116871 l-lactate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 sertraline L-aspartate salt Chemical class 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formas de dosificación de liberación sostenida d esertralina que liberan sertralina a una velocidad entre 1 mgA/h y 40mgA/h. Las formas de dosificación pueden presentar un periodo de retraso inicial durante el cual, la sertralina se libera a una velocidad menor que 1 mgA/h. La presente invención se refiere además a una sal de acetato, a una sal de L-lactato y a una sal de L-aspartato de sertralina, a las composiciones farmacéuticas de las mismas y a los procedimientos de uso de la sal para el tratamiento de varios trastornos y afecciones. La presente invención también se refiere a los procedimientos para la preparación del acetato de sertralina, del L-lactato de sertralina y del L-aspartato de sertralina.Sustained-release dosage forms of esertraline that release sertraline at a rate between 1 mgA / h and 40mgA / h. Dosage forms may have an initial delay period during which sertraline is released at a rate less than 1 mgA / h. The present invention further relates to an acetate salt, an L-lactate salt and a sertraline L-aspartate salt, the pharmaceutical compositions thereof and the methods of using the salt for the treatment of various disorders and conditions. The present invention also relates to the processes for the preparation of sertraline acetate, sertraline L-lactate and sertraline L-aspartate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982571 ECSP982571A (en) | 1998-06-30 | 1998-06-30 | SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982571 ECSP982571A (en) | 1998-06-30 | 1998-06-30 | SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982571A true ECSP982571A (en) | 1999-01-26 |
Family
ID=42043491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982571 ECSP982571A (en) | 1998-06-30 | 1998-06-30 | SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982571A (en) |
-
1998
- 1998-06-30 EC ECSP982571 patent/ECSP982571A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4940402A1 (en) | SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS | |
| ECSP045451A (en) | DOSAGE METHODS AND METHODS FOR CONTROLLED OXICODONE DELIVERY | |
| SV1998000029A (en) | PIRAZINE COMPOUNDS REF. PG3186 | |
| DK1346041T3 (en) | Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease | |
| HRP20040684A2 (en) | 2,4-PYRIMIDINDIAMINE COMPOUNDS AND THEIR USE | |
| AR041566A1 (en) | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
| AR045972A1 (en) | FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS | |
| BR0114799A (en) | Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents | |
| MX9306311A (en) | ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| WO2004078147A3 (en) | Oxytocin controlled release formulations and methods of using same | |
| DK0871434T3 (en) | Oral modified-release pharmaceutical composition containing 5-ASA and method for the treatment of intestinal disorders | |
| BRPI0410044A (en) | dosage form containing pantoprazole as active ingredient | |
| ES2103254T3 (en) | PROCEDURE FOR THE PREPARATION OF AROMATIC HALOSUSTITUTED ACID. | |
| ECSP982571A (en) | SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS | |
| TR200101090T2 (en) | Sertraline mouth concentrate | |
| GT200000087A (en) | POLYMORPH FORMS OF A AZABICICLO CITRATE (2.2.2) OCTAN - 3 - AMINA AND ITS PHARMACEUTICAL COMPOSITIONS. | |
| HN2001000119A (en) | S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF PSYCHIATRIC AND EYE DISORDERS. | |
| UY28111A1 (en) | NEW ORAL IMMEDIATE RELEASE DOSAGE FORM | |
| NO20054157L (en) | Delayed-release venlafaxine formulations | |
| AR031104A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A CARBOXIALQUILETER AND AN ANTIHIPERTENSIVE AGENT, FIRST COMPOSITION FOR USE WITH A SECOND COMPOSITION THAT UNDERSTAND AN ANTIHIPERTENSIVE AGENT AND A CARBOXIALQUILETER RESPECTIVELY, TEAM UNDERSTANDING AN CARBOXIALQUTIETT | |
| BR0311209A (en) | Method of producing pharmaceutical dosage units for oral administration, use of etonogestrel, and tablet | |
| PA8591201A1 (en) | NEW DERIVATIVES CONTAINING PHOSPHORUS | |
| TH43680A (en) | Chertaline salt and sertraline-delayed use patterns | |
| AP2002002662A0 (en) | Sertraline salts and sustained-release dosage forms of sertraline | |
| ECSP993166A (en) | SERTRALINA ORAL CONCENTRATE |